



## Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

November 15, 2019

**The Woodlands, Texas, November 14, 2019** – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference:

- Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:35 p.m. EST in New York, NY.

A live audio webcast for this conference will be available in the “Events” section of the Lexicon website at [www.lexpharma.com/](http://www.lexpharma.com/). An archived version of the webcast will be available on the website for two weeks.

### About Lexicon Pharmaceuticals

Lexicon is a fully integrated biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. In addition to its first commercial product, XERMELO, Lexicon has a pipeline of promising drug candidates in clinical and preclinical development in diabetes and metabolism, oncology and neuropathic pain. For additional information, please visit [www.lexpharma.com](http://www.lexpharma.com).

### Safe Harbor Statement

*This press release contains “forward-looking statements,” including statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development of its drug candidates, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.*

### For Investor Inquiries:

Kimberly Lee, D.O.  
Head of Investor Relations and Corporate Strategy  
Lexicon Pharmaceuticals  
(281) 863-3383  
[klee@lexpharma.com](mailto:klee@lexpharma.com)

### For Media Inquiries:

Chas Schultz  
Executive Director, Corporate Communications and Patient Advocacy  
Lexicon Pharmaceuticals  
(281) 863-3421  
[cschultz@lexpharma.com](mailto:cschultz@lexpharma.com)